K2M Group Holdings, Inc., a medical device company, provides spine and minimally invasive solutions in the United States and internationally. The company offers implants, disposables, and instruments primarily to hospitals for use by spine surgeons to treat spinal pathologies, such as deformity, trauma, and tumor. Its complex spine products include EVEREST, MESA, and MESA 2 deformity spinal systems; NILE alternative and proximal fixation spinal systems; MESA rail deformity spinal systems; Cricket spinal correction rod reduction instrumentation; CAPRI corpectomy cage systems; MESA small stature, rail small stature, and mini spinal systems; SERENGETI complex spine minimally invasive retractor systems; RAVINE complex spine lateral access systems; SANTORINI corpectomy cage systems; YUKON OCT spinal systems; and PALO ALTO cervical static corpectomy cage systems. The company's minimally invasive surgery products consist of EVEREST minimally invasive spinal and XT spinal, SERENGETI minimally invasive retractor, MOJAVE PL 3D expandable interbody, RAVINE lateral access, CASCADIA lateral 3D interbody, ALEUTIAN lateral interbody, and TERRA NOVA minimally invasive access systems. In addition, its degenerative spine products comprise EVEREST degenerative spinal, CASCADIA and ALEUTIAN interbody, SAHARA AL expandable stabilization, RHINE cervical disc, CHESAPEAKE interbody, PYRENEES cervical plate, and BLUE RIDGE hybrid cervical plate systems. Further, the company provides Balance ACS, a platform that includes tools to assist surgeons with obtaining authorization from healthcare insurers. K2M Group Holdings, Inc. markets and sells its products through direct sales employees, independent sales agencies, and distributor partners. The company was founded in 2004 and is headquartered in Leesburg, Virginia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KTWO
CUSIPN/A
Phone703-777-3155
Debt
Debt-to-Equity Ratio0.51
Current Ratio3.48
Quick Ratio2.13
Price-To-Earnings
Trailing P/E Ratio-24.08
Forward P/E Ratio-26.19
P/E GrowthN/A
Sales & Book Value
Annual Sales$258.03 million
Price / Sales3.54
Cash FlowN/A
Price / CashN/A
Book Value$5.59 per share
Price / Book3.75
Profitability
EPS (Most Recent Fiscal Year)($0.87)
Net Income$-37,140,000.00
Net Margins-14.49%
Return on Equity-16.27%
Return on Assets-10.15%
Miscellaneous
Employees484
Outstanding Shares43,600,000
Market Cap$909.03 million
K2M Group (NASDAQ:KTWO) Frequently Asked Questions
What is K2M Group's stock symbol?
K2M Group trades on the NASDAQ under the ticker symbol "KTWO."
How were K2M Group's earnings last quarter?
K2M Group Holdings Inc (NASDAQ:KTWO) announced its quarterly earnings results on Wednesday, August, 1st. The medical device company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.06. The medical device company had revenue of $73.58 million for the quarter, compared to analyst estimates of $70.85 million. K2M Group had a negative net margin of 14.49% and a negative return on equity of 16.27%. The firm's quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.21) earnings per share. View K2M Group's Earnings History.
When is K2M Group's next earnings date?
What price target have analysts set for KTWO?
11 analysts have issued twelve-month price targets for K2M Group's stock. Their predictions range from $22.00 to $29.00. On average, they anticipate K2M Group's share price to reach $25.50 in the next year. This suggests a possible upside of 21.7% from the stock's current price. View Analyst Price Targets for K2M Group.
What is the consensus analysts' recommendation for K2M Group?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for K2M Group in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for K2M Group.
What are Wall Street analysts saying about K2M Group stock?
Here are some recent quotes from research analysts about K2M Group stock:
- 1. According to Zacks Investment Research, "K2M Group Holdings, Inc. is a global medical device company. The Company is focused on designing, developing and commercializing complex spine and minimally invasive spine technologies and techniques. Its products consist of implants, disposables and instruments which are marketed and sold primarily to hospitals for use by spine surgeons. The Company's products include Complex Spine, Minimally Invasive Spine and Degenerative Spine. Its technologies include MESA, Rail 4D, Deformity Cricket, SERENGETI, RAVINE, EVEREST and tifix. K2M Group Holdings, Inc. is headquartered in Leesburg, Virginia. " (7/4/2018)
- 2. Needham & Company LLC analysts commented, "KTWO’s 1Q18 revenue beat while its EBITDA missed consensus. Revenue growth slowed slightly to 8% CC in 1Q18 from 9% CC in 4Q17. Management raised its revenue guidance due to an OUS distribution deal. We think that KTWO is well-positioned for strong growth in 2018 given new products (including its Mojave expandable spacer, Yukon OCT system, Palo Alto corpectomy cage, and Nile proximal fixation system), its new Spanish/Portuguese distributor agreement, and its Brainlab agreement. We reiterate our Buy rating given this and its large discount to peers (2018E EV/sales of 3.0x vs. small/mid-cap growth peers at a median of 8.2x)." (5/2/2018)
Who are some of K2M Group's key competitors?
Some companies that are related to K2M Group include Novocure (NVCR), NuVasive (NUVA), Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Nevro (NVRO), Tandem Diabetes Care (TNDM), Glaukos (GKOS), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), Luminex (LMNX), Cryolife (CRY), Atrion (ATRI), AtriCure (ATRC), Tactile Systems Technology (TCMD) and OraSure Technologies (OSUR).
Who are K2M Group's key executives?
K2M Group's management team includes the folowing people:
- Mr. Eric D. Major, Co-Founder, Chairman, CEO & Pres (Age 48)
- Dr. John Phillip Kostuik, Co-Founder, Chief Medical Officer and Director (Age 80)
- Mr. Gregory S. Cole, Chief Financial Officer (Age 48)
- Mr. Lane E. Major, Chief Operating Officer (Age 39)
- Mr. Dave B. MacDonald, Sr. VP of Operations
Has K2M Group been receiving favorable news coverage?
News articles about KTWO stock have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. K2M Group earned a coverage optimism score of 0.09 on Accern's scale. They also assigned news headlines about the medical device company an impact score of 47.21 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for K2M Group.
Who are K2M Group's major shareholders?
K2M Group's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.98%), Waddell & Reed Financial Inc. (5.09%), Emerald Advisers Inc. PA (2.51%), Cortina Asset Management LLC (2.28%), Penn Capital Management Co. Inc. (1.69%) and Point72 Asset Management L.P. (1.48%). Company insiders that own K2M Group stock include Carson Anderson & Stow Welsh, George Z Moratis, Gregory S Cole and John Philip Md Kostuik. View Institutional Ownership Trends for K2M Group.
Which major investors are selling K2M Group stock?
KTWO stock was sold by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Bank of New York Mellon Corp, Bellevue Group AG, Bank of Montreal Can, Peregrine Capital Management LLC, Sterling Capital Management LLC, ARK Investment Management LLC and Emerald Advisers Inc. PA. Company insiders that have sold K2M Group company stock in the last year include George Z Moratis, Gregory S Cole and John Philip Md Kostuik. View Insider Buying and Selling for K2M Group.
Which major investors are buying K2M Group stock?
KTWO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Penn Capital Management Co. Inc., Point72 Asset Management L.P., Russell Investments Group Ltd., Gamco Investors INC. ET AL, Kopp Investment Advisors LLC, C WorldWide Group Holding A S and Millennium Management LLC. View Insider Buying and Selling for K2M Group.
How do I buy shares of K2M Group?
Shares of KTWO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is K2M Group's stock price today?
One share of KTWO stock can currently be purchased for approximately $20.95.
How big of a company is K2M Group?
K2M Group has a market capitalization of $909.03 million and generates $258.03 million in revenue each year. The medical device company earns $-37,140,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. K2M Group employs 484 workers across the globe.
How can I contact K2M Group?
K2M Group's mailing address is 600 HOPE PARKWAY SE, LEESBURG VA, 20175. The medical device company can be reached via phone at 703-777-3155 or via email at [email protected]
MarketBeat Community Rating for K2M Group (NASDAQ KTWO)
MarketBeat's community ratings are surveys of what our community members think about K2M Group and other stocks. Vote "Outperform" if you believe KTWO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KTWO will underperform the S&P 500 over the long term. You may vote once every thirty days.
